Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease

BACKGROUND: Cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) in patients without cardiovascular or renal disease, a majority of newly diagnosed patients with type 2 diabetes often excluded from clinical trials on this association, is poorly understood. Thus, we investigate the ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Baksh, Sheriza N., Segal, Jodi B., McAdams-DeMarco, Mara, Kalyani, Rita R., Alexander, G. Caleb, Ehrhardt, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561135/
https://www.ncbi.nlm.nih.gov/pubmed/33057387
http://dx.doi.org/10.1371/journal.pone.0240141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561135/
https://www.ncbi.nlm.nih.gov/pubmed/33057387
http://dx.doi.org/10.1371/journal.pone.0240141

Ejemplares similares